Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Director of Global Named Patient Access Strategy & Operations will lead the strategy, design, implementation, and operation of global charged-for named patient access initiatives for Revolution Medicines (“RevMed”). This role plays a key role in facilitating compliant paid access to Revolution Medicines’ investigational therapies through authorized physician-initiated individual patient importation requests in advance of local market authorization. This role will report to the Executive Director – Pancreatic Cancers in the Global Commercialization Development organization and play an integral role in our commitment to supporting appropriate patient access to medicines. This position is based out of our headquarters in Redwood City, CA (remote).
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director